Dravet Syndrome Treatment Approach
For Dravet syndrome, initiate treatment with valproate as first-line therapy, add clobazam as the second agent, and then escalate to stiripentol, fenfluramine, or cannabidiol as adjunctive therapies for refractory seizures. 1, 2
First-Line Treatment Strategy
Valproate (VPA) is the foundational first-line antiseizure medication for Dravet syndrome, with broad-spectrum efficacy against multiple seizure types characteristic of this condition 1, 2. Start with standard dosing and titrate to therapeutic levels while monitoring liver function and ammonia levels.
Clobazam (CLB) should be added as the second agent when valproate alone provides insufficient seizure control 1, 2. This combination forms the backbone of Dravet syndrome management in most regions, though clobazam availability varies by country.
Critical Medication Avoidance
Avoid sodium channel blockers including carbamazepine, lamotrigine, phenytoin, and oxcarbazepine—these medications can paradoxically worsen seizures in Dravet syndrome due to the underlying SCN1A pathophysiology 1.
Second-Line Therapies for Refractory Seizures
When the VPA/CLB combination fails to adequately control seizures, escalate to one of three FDA-approved adjunctive therapies:
Stiripentol (STP)
- FDA-approved in 2018 specifically for Dravet syndrome
- Add to VPA/CLB regimen at 50 mg/kg/day divided into 2-3 doses
- Real-world data shows significant reduction in bilateral convulsive seizures (OR=2.16) and nearly 50% decrease in status epilepticus episodes 3
- Key interaction: Increases CLB and norclobazam levels, potentially causing somnolence—may require CLB dose reduction 1
- Gastrointestinal adverse events increase when combined with VPA 1
Fenfluramine (FFA)
- FDA-approved in 2020
- Start at 0.2 mg/kg/day, titrate to 0.7 mg/kg/day (maximum 26 mg/day)
- Mandatory cardiac monitoring: Echocardiography at baseline, 3 months, then every 6 months due to historical concerns about valvular heart disease (though none documented at low doses used in epilepsy) 1
- Critical interaction: Requires 50% dose reduction when combined with stiripentol 1
Cannabidiol (CBD)
- FDA-approved 2018/2019
- Start at 2.5 mg/kg twice daily, increase to 10 mg/kg twice daily (maximum 20 mg/kg/day)
- Bidirectional interaction with CLB: Increases norclobazam and 7-OH-CBD levels, causing somnolence and sedation 1
- Hepatotoxicity risk: Monitor liver transaminases closely, especially with concomitant VPA—can cause significant elevations requiring dose adjustment or discontinuation 1, 4
Additional Treatment Options
Topiramate has demonstrated efficacy in Dravet syndrome and is frequently used, though not specifically FDA-approved for this indication 1, 2. Warning: Concomitant VPA and topiramate can cause encephalopathy and hyperammonemia 1.
Bromide shows anecdotal efficacy and is commonly used in Germany and Japan 1, 2.
Levetiracetam is frequently tried but evidence suggests limited benefit in Dravet syndrome specifically 5, 6.
Status Epilepticus Management
For acute prolonged seizures or status epilepticus in Dravet syndrome patients:
- Benzodiazepines first: Lorazepam 0.1 mg/kg IV (maximum 2 mg), repeat once if needed 7
- Second-line agents: Levetiracetam 40 mg/kg IV bolus (maximum 2,500 mg) 7
- Refractory cases: Add phenobarbital 10-20 mg/kg IV (maximum 1,000 mg) 7
Monitoring Requirements
Laboratory Parameters
- Valproate: Liver function tests, complete blood count, ammonia levels, drug levels
- Cannabidiol: Liver transaminases (especially with VPA), drug levels
- Fenfluramine: Echocardiography (baseline, 3 months, then q6 months), weight monitoring
- Stiripentol: Monitor for drug interactions affecting CLB levels
Clinical Parameters
- Seizure frequency and duration (convulsive and non-convulsive)
- Growth parameters in children
- Weight changes (particularly with fenfluramine)
- Behavioral changes and cognitive function
- Quality of life assessments
Emerging Disease-Modifying Therapies
Zorevunersen, an antisense oligonucleotide targeting SCN1A haploinsufficiency, shows promising results with median seizure reduction of 58-91% across treatment intervals, along with improvements in quality of life and adaptive behavior 8. This represents a potential paradigm shift toward disease modification rather than symptomatic seizure control alone.
Treatment Selection Algorithm
- Start: Valproate monotherapy
- Add: Clobazam if inadequate control
- Escalate to one of: Stiripentol (if available and tolerated), Fenfluramine (requires cardiac monitoring), or Cannabidiol (monitor liver function)
- Consider: Topiramate or bromide as alternatives
- Avoid: All sodium channel blockers
- Monitor: Drug-drug interactions requiring dose adjustments, particularly STP+CLB, CBD+CLB, CBD+VPA, and FFA+STP
The goal is not just seizure frequency reduction but improvement in overall neurodevelopmental outcomes, quality of life, and reduction in sudden unexpected death in epilepsy (SUDEP) risk 9, 2.